Nuvectis Pharma, Inc. · NASDAQ:NVCT
Nuvectis Pharma — Investor Presentation (April 2023)
23 slides from Nuvectis Pharma's investor presentation, April 2023
Slide 1: Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology April 2023 (NASDAQ: NVCT)
Slide 2: Forward Looking Statements
Forward Looking Statements Nuvectis Pharma, Inc. Certain statements in this presentation constitute “forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical
Slide 3: Nuvectis Pharma – Key Highlights
Nuvectis Pharma – Key Highlights Our Approach to Select novel, rationally-designed drug candidates for serious conditions of unmet need in oncology Precision Medicine A focused clinical/regulatory strategy Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian carcinoma NXP800
Slide 4: Management Team
Management Team Track record of success Jelmyto® (mitomycin) Ron Bentsur Enrique Poradosu, PhD Shay Shemesh Chairman & Chief Executive Officer Chief Scientific & Business Officer Chief Development & Operations Officer NuvectisPharma, Inc. 4
Slide 5: Nuvectis Precision Medicine Pipeline
Nuvectis Precision Medicine Pipeline Drug Discovery and Lead Indication Optimization IND-Enabling Phase 1a Phase 1b Phase 2 Phase 3 Candidate ARID1a-mutated ovarian cancer Fast Track Designation Phase 1b in ARID1a-mutated ovarian cancer in collaboration with NXP800 • clear cell carcinoma ENGOT and
Slide 6: About NXP800
4 About NXP800
Slide 7: NXP800 Key Highlights
NXP800 Key Highlights Precision Medicine HSF1 pathway inhibitor discovered and optimized at the Institute of Cancer Research (ICR) in the UK Approach Substantial efficacy in ARID1a-mutated xenograft models Focused Clinical & Fast Track Designation granted for the treatment of platinum resistan
Slide 8: Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts
Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts (NXP800 vs. Cisplatin) Preclinical proof of concept leading to selection of initial target indications SKOV-3 Model TOV-21G Model Est. Total Est. # of Patients Disease Incidence w/ ARID1a (US) a Deficiency Ovarian Clear Ce
Slide 9: Substantial Antitumor Activity in Additional ARID1a-Mutated Solid Tumors
Substantial Antitumor Activity in Additional ARID1a- Mutated Solid Tumors Additional potential development opportunities SNU-1 Model (Gastric Carcinoma) Est. Total Incidence Est. # of Patients Disease (US) a w/ ARID1a Deficiency Gastric Carcinoma 26,380 6,595 a. Based on data from the American Cance
Slide 10: Substantial Antitumor Activity in Cholangiocarcinoma
Substantial Antitumor Activity in Cholangiocarcinoma Additional potential development opportunities Cholangiocarcinoma (CCA) is a lethal malignancy with poor prognosis arising from the biliary tree Approx. 10,000 new cases/year in the US a a. The cholangiocarcinoma foundation, cholangiocarcinoma
Slide 11: About NXP900
4 About NXP900
Slide 12: NXP900 Key Highlights
NXP900 Key Highlights Discovered at the University of Edinburgh, Scotland Precision Medicine Approach A potent, novel, small molecule inhibitor of YES1/SRC signaling Highly selective Differentiated Unique mechanism of action Features Lack of immunosuppression Ability to cross the blood-b
Slide 13: Structure of SRC Family Kinases (SFK)
Structure of SRC Family Kinases (SFK) Scaffold Domain SH2 and SH3 domains of SRC kinase family members constitute a scaffold to which other pro-oncogenic signaling molecules are recruited inducing pro-oncogenic signals Catalytic Domain SRC kinase family members (such as Src and Yes1) transmit pro-on
Slide 14: NXP900 Completely Shuts Down Signaling of SFK
NXP900 Completely Shuts Down Signaling of SFK Differentiated vs. other multi-kinase inhibitors that only achieve a partial SRC pathway shut down NXP900: Complete shutdown of Other multi-kinase inhibitors: Partial No inhibitor: Fully active SRC the SRC pathway shutdown of the SRC pathway NON- FNCTION
Slide 15: NXP900 Kinome Profiling Demonstrates High Selectivity
NXP900 Kinome Profiling Demonstrates High Selectivity NXP900 Dasatinib Note: Dasatinib data from Remsing Rix et al., Leukemia 23, 477–485 (2009), NXP900 data from AACR 2022. NuvectisPharma, Inc. 15
Slide 16: Targeting YES1 in Cancers of Squamous Cell Origin
Targeting YES1 in Cancers of Squamous Cell Origin YES1 gene amplification drives tumor growth via activating phosphorylation of YAP1. YES1 gene amplification is prevalent in cancers of squamous cell origin. Genetic mutation in FAT1 and other alterations along the Hippo pathway are common in ca
Slide 17: Preclinical Proof of Concept
Preclinical Proof Squamous Cell Cancers of Concept Group 4 Medulloblastoma Potential Combination Strategies NuvectisPharma, Inc. 17
Slide 18: Squamous Cell Cancers
Squamous Cell Cancers NXP900 demonstrated robust antitumor activity in xenograft models of squamous cell cancers * YES1 gene amplification is a known genetic alteration in KYSE70 cells * Heterozygous FAT1 copy loss is a known genetic alteration in Cal27 cells NuvectisPharma, Inc. 18
Slide 19: Group 4 Medulloblastoma
Group 4 Medulloblastoma SRC signaling is a hallmark of Group 4 medulloblastoma a Treatment Window Presented June 12th, 2022 at SIOPE Brain Tumor Group in Hamburg, Germany, by the Pediatric Solid Tumor Biology and Therapeutics Team (led by Prof. Louis Chesler of The Institute of Cancer Research in Lo
Slide 20: Potential Combination Strategies
Potential Combination Strategies YES1 (in NSCLC) and SRC (in mCRPC) are implicated in development of resistance to osimerinib (Tagrisso) and enzalutamide (Xtandi) NXP900 in combination with enzalutamide overcomes NXP900 in combination with osimertinib overcomes resistance in vitro resistance in vivo
Slide 21: Financial and NVCT Stock Highlights
Financial and NVCT Stock Highlights Cash position • $20M as of 12-31-2022 • Runway into H2 2024 3 Co-founders own approximately 35% Covering analysts • HC Wainwright & Co – Joe Pantginis • Roth Capital Partners – Jonathan Aschoff • Ladenburg Thalmann – Aydin Huseynov NuvectisPharma, Inc. 21
Slide 22: Nuvectis Investment Highlights
Nuvectis Investment Highlights Precision medicine pipeline for serious conditions of unmet medical need in oncology Initiation of the NXP800 Phase 1b in ARID1a-mutated ovarian cancers Significant Milestones IND/equivalent submission for NXP900 followed by commencement of the Phase 1 program Expe
Slide 23: Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology April 2023 (NASDAQ: NVCT)